SCHEMBL1491225

SCHEMBL1491225

IC1CCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8145346 1.00
SCHEMBL12064988 1.00
SCHEMBL24741443 0.90
SCHEMBL5184661 0.90
SCHEMBL18658857 0.90
SCHEMBL14908536 0.88
SCHEMBL10037574 0.78
SCHEMBL359800 0.69
SCHEMBL28042158 0.69
SCHEMBL25045822 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111511725-A Synthesis of 1:1:1 cocrystals of 1-cyano-2- (4-cyclopropyl-benzyl) -4- (β -D-glucopyranos-1-yl) -benzene, L-proline and water 勃林格殷格翰维特梅迪卡有限公司 2020-08-07 CN claimed
CN-105153137-A Preparation method of empagliflozin SHANGHAI INST TECHNOLOGY 2015-12-16 CN claimed
CN-119464281-A SiRNA, siRNA conjugate or prodrug thereof for inhibiting DGAT2 gene expression, pharmaceutical composition and application 北京福元医药股份有限公司 2025-02-18 CN disclosed
CN-119464279-A SiRNA for inhibiting SMAD family member 3 expression, conjugate, pharmaceutical composition and application thereof 北京福元医药股份有限公司 2025-02-18 CN disclosed
CN-118421622-A SiRNA for inhibiting angiopoietin-like protein 8 gene expression, conjugate, pharmaceutical composition and application thereof 北京福元医药股份有限公司 2024-08-02 CN disclosed
CN-117757790-A siRNA for inhibiting SCAP gene expression, conjugate, pharmaceutical composition and application thereof 北京福元医药股份有限公司 2024-03-26 CN disclosed
WO-2024054766-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER MITO BIOPHARMA, LLC (US) 2024-03-14 WO disclosed
CN-117645995-A SiRNA for inhibiting expression of asialoglycoprotein receptor gene, conjugate, pharmaceutical composition and application thereof 北京福元医药股份有限公司 2024-03-05 CN disclosed
CN-117070517-A siRNA for inhibiting expression of angiotensinogen, conjugate, pharmaceutical composition and application thereof 北京福元医药股份有限公司 2023-11-17 CN disclosed
WO-2023196409-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-12 WO disclosed
CN-116769780-A siRNA for inhibiting expression of complement factor B, conjugate and pharmaceutical composition thereof and use thereof 北京福元医药股份有限公司 2023-09-19 CN disclosed
CN-1572754-A Method for producing organic compound by substituting halogen atoms MITSUI CHEMICALS INC (JP) 2005-02-02 CN disclosed
US-20040256743-A1 Method for producing organic compound by substituting halogen atoms MITSUI CHEMICALS, INC. (JP) 2004-12-23 US disclosed
EP-1485387-A1 CARBAMATES AS HIV PROTEASE INHIBITORS BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2004-12-15 EP disclosed
EP-1486479-A1 Method for producing organic compounds by substituting halogen atoms MITSUI CHEMICALS, INC. (JP) 2004-12-15 EP disclosed
US-20040039016-A1 HIV protease inhibitors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-02-26 US disclosed
WO-2003078438-A1 CARBAMATES AS HIV PROTEASE INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2003-09-25 WO disclosed
EP-1088098-A2 FITNESS ASSAY AND ASSOCIATED METHODS UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND SOCIAL SERVICES (US) 2001-04-04 EP disclosed
WO-1999067254-A2 MULTI-DRUG RESISTANT RETROVIRAL PROTEASE INHIBITORS AND USE THEREOF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1999-12-29 WO disclosed
WO-1999067417-A2 FITNESS ASSAY AND ASSOCIATED METHODS THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1999-12-29 WO disclosed